The risk or severity of adverse effects can be increased when Flurazepam is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Loxapine is combined with Amitriptyline. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline. The serum concentration of Naloxegol can be increased when it is combined with Amitriptyline. Pargyline may increase the serotonergic activities of Amitriptyline. Amitriptyline may increase the QTc-prolonging activities of Dronedarone. Tedizolid Phosphate may increase the serotonergic activities of Amitriptyline. The risk or severity of adverse effects can be increased when Levorphanol is combined with Amitriptyline. The serum concentration of Amitriptyline can be increased when it is combined with Thiorphan. Levothyroxine may increase the arrhythmogenic activities of Amitriptyline. Amitriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. The risk or severity of adverse effects can be increased when Pipamperone is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Tiagabine. The metabolism of Amitriptyline can be decreased when combined with Eslicarbazepine acetate. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ethotoin. The risk or severity of adverse effects can be increased when Methaqualone is combined with Amitriptyline. The metabolism of Amitriptyline can be decreased when combined with Armodafinil. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Doxepin. The risk or severity of adverse effects can be increased when Sertraline is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Vilazodone is combined with Amitriptyline. Amitriptyline may decrease the antihypertensive activities of Dihydroergotamine. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Pizotifen. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyamemazine. Amitriptyline may increase the QTc-prolonging activities of Lenvatinib. The risk or severity of adverse effects can be increased when Remifentanil is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Brompheniramine. The metabolism of Amitriptyline can be decreased when combined with Isoniazid. The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Amitriptyline. The metabolism of Amitriptyline can be decreased when combined with Pioglitazone. The risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Carisoprodol. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Formoterol. The risk or severity of adverse effects can be increased when Etorphine is combined with Amitriptyline. L-Tryptophan may increase the serotonergic activities of Amitriptyline. Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. The serum concentration of Amitriptyline can be increased when it is combined with Quinapril. The serum concentration of Amitriptyline can be decreased when it is combined with Peginterferon alfa-2b. The risk or severity of adverse effects can be increased when Rufinamide is combined with Amitriptyline. The serum concentration of Amitriptyline can be increased when it is combined with Cinacalcet. Amitriptyline may increase the QTc-prolonging activities of Leuprolide. Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. The risk or severity of adverse effects can be increased when Benperidol is combined with Amitriptyline. Amitriptyline may decrease the antihypertensive activities of Bethanidine. The metabolism of Amitriptyline can be decreased when combined with Telithromycin. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Desipramine. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclobenzaprine. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ziconotide. The risk or severity of adverse effects can be increased when Halothane is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Lorazepam is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Dezocine is combined with Amitriptyline. Amitriptyline may increase the anticoagulant activities of Warfarin. The serum concentration of Amitriptyline can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride. The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amitriptyline. The metabolism of Amitriptyline can be decreased when combined with Ticagrelor. The serum concentration of Amitriptyline can be increased when it is combined with Ceritinib. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Ritodrine. The risk or severity of adverse effects can be increased when Butamben is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Clidinium. Amitriptyline may increase the anticoagulant activities of Phenindione. The serum concentration of Brentuximab vedotin can be increased when it is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Triazolam is combined with Amitriptyline. The serum concentration of Amitriptyline can be increased when it is combined with Perindopril. The serum concentration of Tizanidine can be increased when it is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Enflurane is combined with Amitriptyline. The metabolism of Amitriptyline can be decreased when combined with Boceprevir. The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amitriptyline. The serum concentration of Prucalopride can be increased when it is combined with Amitriptyline. The metabolism of Amitriptyline can be decreased when combined with Thiotepa. Amitriptyline may increase the stimulatory activities of Midomafetamine. Amitriptyline may increase the vasopressor activities of Metaraminol. The metabolism of Amitriptyline can be decreased when combined with Manidipine. The risk or severity of adverse effects can be increased when Perospirone is combined with Amitriptyline. Amitriptyline may decrease the antihypertensive activities of Apomorphine. The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Nalbuphine is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Flibanserin. Amitriptyline may increase the QTc-prolonging activities of Pentamidine. The risk or severity of adverse effects can be increased when Canertinib is combined with Amitriptyline. The serum concentration of Amitriptyline can be increased when it is combined with Cobicistat. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Dextromethorphan. The risk or severity of adverse effects can be increased when Mesoridazine is combined with Amitriptyline. The serum concentration of Amitriptyline can be increased when it is combined with Spirapril. Amitriptyline may increase the QTc-prolonging activities of Arsenic trioxide. Amitriptyline may increase the sedative activities of Pramipexole. Amitriptyline may increase the QTc-prolonging activities of Flecainide. Amitriptyline may increase the QTc-prolonging activities of Haloperidol. The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Metaxalone. Amitriptyline may increase the QTc-prolonging activities of Dolasetron. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Pipotiazine. The metabolism of Amitriptyline can be decreased when combined with Modafinil. The risk or severity of adverse effects can be increased when Zaleplon is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amitriptyline. The serum concentration of Amitriptyline can be increased when it is combined with Faldaprevir. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Indalpine. The metabolism of Amitriptyline can be decreased when combined with Tenofovir disoproxil. The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amitriptyline. Phenoxypropazine may increase the serotonergic activities of Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Bifeprunox. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Orciprenaline. Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. The serum concentration of Conivaptan can be increased when it is combined with Amitriptyline. Amitriptyline may decrease the antihypertensive activities of Levonordefrin. The metabolism of Amitriptyline can be decreased when combined with Sulfadiazine. The risk or severity of adverse effects can be increased when Remoxipride is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Cabergoline is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Entacapone. The risk or severity of adverse effects can be increased when Etidocaine is combined with Amitriptyline. The metabolism of Amitriptyline can be decreased when combined with Sorafenib. The risk or severity of adverse effects can be increased when Zotepine is combined with Amitriptyline. The metabolism of Amitriptyline can be decreased when combined with Fluvastatin. The serum concentration of Everolimus can be increased when it is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Scopolamine. The serum concentration of Amitriptyline can be increased when it is combined with Lisinopril. The risk or severity of adverse effects can be increased when Oxycodone is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Brotizolam is combined with Amitriptyline. Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. The serum concentration of Amitriptyline can be increased when it is combined with Omapatrilat. The risk or severity of adverse effects can be increased when Pramocaine is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Amitriptyline is combined with Fexofenadine. The risk or severity of adverse effects can be increased when Sufentanil is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Cinchocaine is combined with Amitriptyline. The metabolism of Amitriptyline can be increased when combined with Phenytoin. The metabolism of Amitriptyline can be decreased when combined with Saquinavir. The risk or severity of adverse effects can be increased when Tandospirone is combined with Amitriptyline. The serum concentration of Amitriptyline can be increased when it is combined with Alogliptin. The serum concentration of Yohimbine can be increased when it is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Gepirone is combined with Amitriptyline.